Mabxience Sets Out Investment Plans Under Fresenius Ownership

New Bioreactor At Genhelix Site In Spain Is A Milestone For Biosimilars Developer

 
• By Dave Wallace

Unveiling plans to install a new bioreactor at its Genhelix site in Spain, mAbxience is bolstering its biosimilars manufacturing capabilities and CDMO capacity under the majority ownership of Fresenius Kabi.

Capacity building
mAbxience is expanding capacity at its Genhelix site • Source: Shutterstock

Biologics and biosimilars specialist mAbxience has set out what it describes as “ambitious growth plans” by unveiling an investment in installing a new 4,000L single-use bioreactor at its Genhelix site in Spain.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Manufacturing

More from Business